Loading...
•
Dec 31, 2024
Savara Q4 2024 Earnings Report
Savara reported an increased net loss in Q4 2024, driven by higher R&D and G&A expenses as it advanced the MOLBREEVI program.
Key Takeaways
In Q4 2024, Savara posted a net loss of $29.04 million or $(0.13) per share, primarily due to increased investment in research and development and commercial preparation for MOLBREEVI. The company ended the quarter with strong liquidity, holding $196.33 million in cash and short-term investments.
Net loss widened to $29.04 million from $16.1 million in Q4 2023.
EPS came in at $(0.13), down from $(0.09) a year earlier.
R&D expenses nearly doubled year-over-year to $23.3 million.
Cash and short-term investments totaled $196.33 million at quarter-end.
Savara
Savara
Forward Guidance
Savara expects to maintain a strong financial position with a projected cash runway into 2Q 2027 and is focused on advancing regulatory and commercial activities for MOLBREEVI.
Positive Outlook
- Completed BLA submission for MOLBREEVI to the FDA.
- Requested Priority Review, with potential approval by end of 2025.
- Commercial launch preparations underway for early 2026.
- Orphan Drug and Breakthrough Therapy Designations obtained.
- Strong cash position with $196M on hand excluding debt financing.
Challenges Ahead
- Increased net loss due to higher R&D and G&A expenses.
- No product revenue reported in Q4 2024.
- Operational losses widened year-over-year.
- Pending regulatory approval adds uncertainty to timelines.
- Continued reliance on capital markets and debt for funding.